Hope on the Horizon: Brilaroxazine’s Promise for Schizophrenia Patients
DelveInsight Blog
by
3d ago
Brilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine ..read more
Visit website
Iclepertin: Bridging the Gap in CIAS Treatment – the Answer to an Unmet...
DelveInsight Blog
by
3d ago
Despite the urgent need for novel treatments, drug development for cognitive impairment associated with schizophrenia ..read more
Visit website
DOC1021 – Unveiling Hope: Diakonos Oncology’s Breakthrough in Glioblast...
DelveInsight Blog
by
3d ago
Glioblastoma or Glioblastoma Multiforme (GBM) represents the most common primary tumor of the central nervous ..read more
Visit website
Breaking Boundaries: The Promise of LYN-005 in Schizophrenia Treatment
DelveInsight Blog
by
3d ago
LYN-005’s once-weekly dosing regimen reduces the pill burden for individuals with schizophrenia and schizoaffective disorders ..read more
Visit website
The Unmet Needs in Glaucoma Treatment: Bridging Gaps for Better Vision Care
DelveInsight Blog
by
3d ago
Glaucoma, often dubbed as the “silent thief of sight,” poses a significant challenge in the ..read more
Visit website
Beyond Symptom Management: RL-007’s Promise for Cognitive Enhancement i...
DelveInsight Blog
by
3d ago
In the landscape of schizophrenia treatment, there are significant gaps that affect patients' lives profoundly ..read more
Visit website
Potential of EGFR Inhibitors: A Promising Avenue in Cancer Treatment
DelveInsight Blog
by
1w ago
In the realm of cancer treatment, the development of targeted therapies has been nothing short ..read more
Visit website
Advances in Non-Muscle Invasive Bladder Cancer Treatment: Exploring Emerging ...
DelveInsight Blog
by
1w ago
Non-muscle-invasive bladder cancer represents a category of bladder cancer where the tumor is confined to ..read more
Visit website
Gene Therapies for Epidermolysis Bullosa Treatment: The Next Frontier in Derm...
DelveInsight Blog
by
1w ago
Epidermolysis bullosa is a genetic skin condition marked by severe skin sensitivity and the formation ..read more
Visit website
Regeneron’s Odronextamab BLA; Novo Nordisk’s Cardior Pharmaceuticals Acquisit...
DelveInsight Blog
by
1w ago
Regeneron Updates Progress on Biologics License Application for Odronextamab Regeneron Pharmaceuticals, Inc. has announced that ..read more
Visit website

Follow DelveInsight Blog on FeedSpot

Continue with Google
Continue with Apple
OR